Godwin Uzomba
Endocrinology, Diabetes & Metabolism · Charlotte, NCNPI 1659376051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 24.2% of the total. Reporting peaked in 2020 at $1,129 and has fallen 97.3% since, to $31 in 2023.
Across 145 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$585
- AstraZeneca$357
- Johnson & Johnson$201
- Merck$126
- Amarin Pharma, Inc.$124
- Boehringer Ingelheim$119
- plus $906 from 23 others
What the payments were for
- Food & beverage$2,417100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $585 |
| AstraZeneca | 15 | $357 |
| Johnson & Johnson | 13 | $201 |
| Merck | 8 | $126 |
| Amarin Pharma, Inc. | 8 | $124 |
| Boehringer Ingelheim | 5 | $119 |
| Bausch Health US, LLC | 3 | $80 |
| Mannkind Corporation | 2 | $78 |
| Lilly USA, LLC | 5 | $74 |
| AbbVie | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Dexcom, Inc. | 3 | $56 |
| MDD US Operations, LLC | 3 | $50 |
| Bayer | 3 | $45 |
| Insulet Corporation | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| Medtronic(2 entities) | 2 | $26 |
| Genentech USA, Inc. | 2 | $26 |
| Alfasigma USA, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$2,417 in reported general payments places this provider in the 60th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 27 | $110 |
| Ondansetron OdtOndansetron | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Charlotte
- Charles UpchurchCharlotte$343K
- Adam SpitzCharlotte$33K
- Raymond StadiemCharlotte$32K
- Nisha NathanCharlotte$31K
- David BrantleyCharlotte$27K
- Kanakasabai NarasimhanCharlotte$25K
- Elizabeth HarrisCharlotte$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.